UNSPSC 51401506: Doxefazepam

This classification denotes a benzodiazepine with the molecular formula C17H14ClFN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 231RV72C8L, chemically known as 7-chloro-5-(o-fluorophenyl)-1,3-dihydro-3-hydroxy-1-(2-hydroxyethyl)-2h-1,4-benzodiazepin-2-one but generally known as doxefazepam, which bears US NIH Compound Identifier 38668. European Medicines Agency schedules Doxefazepam in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06385MIG.

UNSPSC 51401506 Doxefazepam, a Commodity code, nominally addresses a single pharmaceutical product but shows little recent state and local procurement activity aligned with that specific drug. The three recent opportunities posted under this code involve broader pharmaceutical procurement: naloxone and drug deactivation systems for community health support, direct-to-manufacturer prescription programs for state employee health plans, and multi-source generic pharmaceuticals and OTC products through cooperative purchasing. State and local buyers using this code span county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The work involves competitive bid processes for pharmaceutical product supply, manufacturer direct-contracting feasibility studies, and wholesaler-distributed generic medication procurement to support government health programs and employees.

Activity appears across Florida, Texas, and Minnesota with broader multistate reach through cooperative purchasing vehicles. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023 (note: posted date appears June 30, 2026, but stated due date is from 2023, suggesting a data inconsistency in the source). The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities for direct manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 with a March 26, 2026 response deadline to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through authorized wholesalers to participating state and local facilities including Oregon, effective July 1, 2026. The mismatch between the Commodity code's specific drug focus and the actual scope of recent solicitations suggests this code captures pharmaceutical procurement more broadly at the state and local level.